Genetic Technologies (NASDAQ:GENE) Receives Media Sentiment Rating of -0.16
Media coverage about Genetic Technologies (NASDAQ:GENE) has been trending somewhat negative on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Genetic Technologies earned a media sentiment score of -0.16 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s analysis:
- Cancer: Technology Fights Back (healthtechzone.com)
- FDA Officials Study Alternative Approach to Presenting Risk Info in TV Drug Ads (raps.org)
- Inside the Secret World of Global Food Spies (bloomberg.com)
- Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa (globenewswire.com)
- DVAX Plunges On Delay In Approval, FDA Nod For ABBV’s HCV Drug, ABIO On Radar (rttnews.com)
Shares of Genetic Technologies (NASDAQ GENE) traded down 3.6671% during trading on Tuesday, reaching $0.7802. 97,503 shares of the company were exchanged. Genetic Technologies has a one year low of $0.75 and a one year high of $2.89. The company’s market capitalization is $12.67 million. The firm’s 50 day moving average price is $0.87 and its 200 day moving average price is $1.05.
ILLEGAL ACTIVITY NOTICE: “Genetic Technologies (NASDAQ:GENE) Receives Media Sentiment Rating of -0.16” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/08/genetic-technologies-nasdaqgene-receives-media-impact-rating-of-0-16-updated-updated-updated.html.
Genetic Technologies Company Profile
Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.
Receive News & Stock Ratings for Genetic Technologies Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies Ltd and related stocks with our FREE daily email newsletter.